However, with recent advances in the treatment of metastatic/recurrent breast cancer, preserving patient QoL has become more manageable due to the availability of more tolerable agents, such as hormone therapy and CDK4/6 inhibitors [13, 19]. The gene discussed is CDK4; the disease is breast carcinoma.